Product
Adynovate
Aliases
Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol
2 clinical trials
2 indications
Indication
Hemophilia AIndication
Coagulation factor VIIIClinical trial
A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)Status: Active (not recruiting), Estimated PCD: 2024-10-08
Clinical trial
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement TherapiesStatus: Recruiting, Estimated PCD: 2025-07-01